Cargando…
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells
High attrition rates of novel anti-cancer drugs highlight the need for improved models to predict toxicity. Although polo-like kinase 1 (Plk1) inhibitors are attractive candidates for drug development, the role of Plk1 in primary cells remains widely unexplored. Therefore, we evaluated the utility o...
Autores principales: | Raab, Monika, Kappel, Sven, Krämer, Andrea, Sanhaji, Mourad, Matthess, Yves, Kurunci-Csacsko, Elisabeth, Calzada-Wack, Julia, Rathkolb, Birgit, Rozman, Jan, Adler, Thure, Busch, Dirk H., Esposito, Irene, Fuchs, Helmut, Gailus-Durner, Valérie, Klingenspor, Martin, Wolf, Eckhard, Sänger, Nicole, Prinz, Florian, Angelis, Martin Hrabě de, Seibler, Jost, Yuan, Juping, Bergmann, Martin, Knecht, Rainald, Kreft, Bertolt, Strebhardt, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144583/ https://www.ncbi.nlm.nih.gov/pubmed/21772266 http://dx.doi.org/10.1038/ncomms1395 |
Ejemplares similares
-
PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells
por: Raab, Monika, et al.
Publicado: (2018) -
Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells
por: Raab, Monika, et al.
Publicado: (2014) -
Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification
por: Gasimli, Khayal, et al.
Publicado: (2022) -
A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1
por: Raab, Monika, et al.
Publicado: (2021) -
Correction: A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1
por: Raab, Monika, et al.
Publicado: (2023)